Inventor
ANDERSON KENNETH C
US32 patents
⚠️ This page may combine multiple inventors who share the name “ANDERSON KENNETH C”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
DANA FARBER CANCER INST INC
14 patentsUS9988343B2Jun 5, 2018
Inhibitors of histone deacetylase
DANA FARBER CANCER INST INC7 citations83
US9950047B2Apr 24, 2018
XBP1, CD138, and CS1 peptides, pharmaceutical compositions that include the peptides, and methods of using such peptides and compositions
DANA FARBER CANCER INST INC9 citations80
US11517591B2Dec 6, 2022
Immunogenic peptides specific to BCMA and TACI antigens
DANA FARBER CANCER INST INC1 citations59
US11083783B2Aug 10, 2021
XBP1, CD138, and CS1 peptides
DANA FARBER CANCER INST INC0 citations59
US12005073B2Jun 11, 2024
Methods for modulating regulatory T cells, regulatory b cells, and immune responses using modulators of the april-taci interaction
DANA FARBER CANCER INST INC0 citations56
US11465983B2Oct 11, 2022
USP7 inhibitors for treating multiple myeloma
DANA FARBER CANCER INST INC1 citations53
US11702402B2Jul 18, 2023
Small molecules that block proteasome-associated ubiquitin receptor RPN13 function and uses thereof
DANA FARBER CANCER INST INC0 citations51
US11802132B2Oct 31, 2023
Small molecules for inducing selective protein degradation and uses thereof
DANA FARBER CANCER INST INC0 citations50
US11447467B2Sep 20, 2022
Compounds for the degradation of STK4 and treatment of hematologic malignancies
DANA FARBER CANCER INST INC0 citations49
US8026230B2Sep 27, 2011
Methods and compositions for treating cancer using proteasome inhibitors
DANA FARBER CANCER INST INC0 citations49
US12448429B2Oct 21, 2025
T cell receptors specific to b-cell maturation antigen for treatment of cancer
DANA FARBER CANCER INST INC0 citations48
US10302644B2May 28, 2019
Compositions and methods for treating multiple myeloma
DANA FARBER CANCER INST INC0 citations47
US12109266B2Oct 8, 2024
Modulating gabarap to modulate immunogenic cell death
DANA FARBER CANCER INST INC0 citations41
US9969679B2May 15, 2018
Anti-proliferative compounds and uses thereof
DANA FARBER CANCER INST INC0 citations36
ANDERSON KENNETH C
5 patentsUS8999289B2Apr 7, 2015
Treatment of protein degradation disorders
ANDERSON KENNETH C16 citations90
US8632772B2Jan 21, 2014
Methods of treating multiple myeloma using combination therapies based on anti-CS1 antibodies
ANDERSON KENNETH C7 citations77
US8722724B2May 13, 2014
Compositions and methods for treating neoplastic diseases
ANDERSON KENNETH C4 citations70
US8466147B2Jun 18, 2013
Use of reversine and analogs for treatment of cancer
ANDERSON KENNETH C2 citations53
US8685954B2Apr 1, 2014
Methods and compositions for treating cancer using proteasome inhibitors
ANDERSON KENNETH C0 citations49
ACETYLON PHARMACEUTICALS INC
3 patentsUS11337975B2May 24, 2022
Pharmaceutical combinations comprising a histone deacetylase inhibitor and a CD38 inhibitor and methods of use thereof
ACETYLON PHARMACEUTICALS INC2 citations70
US12053468B2Aug 6, 2024
Pharmaceutical combinations comprising a histone deacetylase inhibitor and a CD38 inhibitor and methods of use thereof
ACETYLON PHARMACEUTICALS INC0 citations59
US11497746B2Nov 15, 2022
Pharmaceutical combinations comprising a histone deacetylase inhibitor and a programmed death-ligand 1 (PD-L1) inhibitor and methods of use thereof
ACETYLON PHARMACEUTICALS INC0 citations59